Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Mar 18;41(3):227–237. doi: 10.1111/1440-1681.12204

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Authors. Clinical and Experimental Pharmacology and Physiology Published by Wiley Publishing Asia Pty Ltd.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Fig. 8 — (a) Plasma and (b) kidney angiotensin (Ang) II concentrations and (c) kidney epoxyeicosatrienoic acids (EETs) : dihydroxyeicosatrienoic acids (DHETEs) ratio, measured 20 weeks (late phase) after 5/6 renal mass reduction (5/6 NX), in sham-operated Hannover Sprague-Dawley rats (HanSD; transgene negative; ), heterozygous Ren-2 transgenic rats (TGR; ▪), in vehicle (water)-treated 5/6 NX TGR (), in 5/6 NX TGR treated with combined renin–angiotensin system (RAS) blockade with trandolapril, an angiotensin-converting enzyme inhibitor, and losartan, an angiotensin receptor blocker () and (d) 5/6 NX TGR treated with the soluble epoxide hydrolase inhibitor cis-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid (). Data are the mean ± SEM. *P < 0.05 compared with sham-operated HanSD rats; ^†P < 0.05 compared with sham-operated TGR. (), HanSD; (), 5/6 NX TGR + sEHi; (▪), 5/6 NX TGR + RAS blockade.

Inline graphic — (a) Plasma and (b) kidney angiotensin (Ang) II concentrations and (c) kidney epoxyeicosatrienoic acids (EETs) : dihydroxyeicosatrienoic acids (DHETEs) ratio, measured 20 weeks (late phase) after 5/6 renal mass reduction (5/6 NX), in sham-operated Hannover Sprague-Dawley rats (HanSD; transgene negative; ), heterozygous Ren-2 transgenic rats (TGR; ▪), in vehicle (water)-treated 5/6 NX TGR (), in 5/6 NX TGR treated with combined renin–angiotensin system (RAS) blockade with trandolapril, an angiotensin-converting enzyme inhibitor, and losartan, an angiotensin receptor blocker () and (d) 5/6 NX TGR treated with the soluble epoxide hydrolase inhibitor cis-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid (). Data are the mean ± SEM. *P < 0.05 compared with sham-operated HanSD rats; ^†P < 0.05 compared with sham-operated TGR. (), HanSD; (), 5/6 NX TGR + sEHi; (▪), 5/6 NX TGR + RAS blockade.